Letteratura scientifica selezionata sul tema "Tuberculose – Cameroun"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Tuberculose – Cameroun".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Articoli di riviste sul tema "Tuberculose – Cameroun":
Simo, L., E. W. Pefura, E. Afane Ze e C. Kuaban. "Particularités de la tuberculose chez le sujet âgé, Yaoundé, Cameroun". Revue des Maladies Respiratoires 31 (gennaio 2014): A95. http://dx.doi.org/10.1016/j.rmr.2013.10.334.
Balkissou, A. D., E. Pefura-Yone, A. Kuate-Kuate, N. Kanko, E. Nga-Nkomo, H. Fatimé-Abaicho, P. Enono-Edende e E. Afane-Ze. "Devenir des patients traités pour tuberculose dans la ville de Yaoundé, Cameroun". Revue des Maladies Respiratoires 33 (gennaio 2016): A42. http://dx.doi.org/10.1016/j.rmr.2015.10.665.
Balkissou, A. D., E. W. Pefura-Yone, V. Poka-Mayap e C. Kuaban. "Facteurs prédictifs de devenir défavorable au cours de la tuberculose au Cameroun". Revue des Maladies Respiratoires Actualités 12, n. 1 (gennaio 2020): 170. http://dx.doi.org/10.1016/j.rmra.2019.11.380.
Djouda Feudjio, Yves Bertrand. "Réseaux relationnels et processus de soutien aux malades de la tuberculose au Cameroun". Redes. Revista hispana para el análisis de redes sociales 18, n. 1 (22 gennaio 2010): 145. http://dx.doi.org/10.5565/rev/redes.391.
Pefura Yone, E. W., A. Evouna Mbarga e C. Kuaban. "Impact de l’infection à VIH sur la tuberculose de l’enfant à Yaoundé, Cameroun". Revue des Maladies Respiratoires 29, n. 9 (novembre 2012): 1095–103. http://dx.doi.org/10.1016/j.rmr.2012.05.017.
Balkissou, A., E. Pefura-Yone, A. Kuate-Kuate, A. Ntyo’o-Nkoumou, V. Poka-Mayap, H. Fatime-Abaicho, P. Enono-Edende e C. Kuaban. "Profil épidémiologique et clinique des patients adultes atteints de tuberculose à Yaoundé, Cameroun". Revue des Maladies Respiratoires 33 (gennaio 2016): A142. http://dx.doi.org/10.1016/j.rmr.2015.10.265.
Pefura Yone, E., H. Fatime Abaicho e P. Enono Edende. "Épidémiologie et issue de traitement de la tuberculose de l’enfant à Yaoundé, Cameroun". Revue des Maladies Respiratoires 33 (gennaio 2016): A161. http://dx.doi.org/10.1016/j.rmr.2015.10.320.
Simo Epse Nenwouo, L., E. Pefura Yone, H. Fatime Abaicho e P. Enono Edende. "Épidémiologie et issue de traitement de la tuberculose de l’enfant à Yaoundé, Cameroun". Revue des Maladies Respiratoires 33 (gennaio 2016): A162—A163. http://dx.doi.org/10.1016/j.rmr.2015.10.323.
Tchieche Epse Kamgue, C., e N. Juergen. "Douze ans de prise en charge programmatique de la tuberculose multirésistante au Cameroun". Revue des Maladies Respiratoires 34 (gennaio 2017): A222—A223. http://dx.doi.org/10.1016/j.rmr.2016.10.532.
Awa, Daniel Nzingu, Aboubakar Njoya, A. C. Ngo e F. N. Ekue. "L'état sanitaire des porcs au Nord Cameroun". Revue d’élevage et de médecine vétérinaire des pays tropicaux 52, n. 2 (1 febbraio 1999): 93–98. http://dx.doi.org/10.19182/remvt.9692.
Tesi sul tema "Tuberculose – Cameroun":
Ngo, Niobe-Eyangoh Sara Irène. "Epidémiologie moléculaire de la tuberculose au Cameroun". Paris 7, 2003. http://www.theses.fr/2003PA077086.
BOGLI, THIERRY. "Propositions d'une methode de gestion originale des malades atteints de tuberculose pulmonaire en milieu tropical : d'apres une experience personnelle conduite a l'hopital de ndoungue (cameroun)". Clermont-Ferrand 1, 1989. http://www.theses.fr/1989CLF13010.
Tantchou, Yakam Josiane Carine. "Comment naissent les politiques verticales de santé en Afrique ? : réinterroger le passé et le présent à partir de la lutte contre la trypanosomiase et la tuberculose au Cameroun". Paris, EHESS, 2006. http://www.theses.fr/2006EHES0238.
The thesis seek to answers three questions: how can we explain the emergence of selective health programs in Africa? How can we explain the repetitive failures of health policies in Africa ? What justifies the "eagerness" to improve the health of the poor (countries). As answer to the first question, the author notes that selective health policies are not always based on the report of a critical epidemiologic situation. They are often the initiative of actors inserted in power networks, able to mobilize interest and financial resources. The thesis raises the question of "eagerness" to cooperate or improve the health of the poor (countries). Refuting the humanitarian argument, the author uses Michel Foucault analysis of the "racisme d'Etat" and explains this by the desire "de faire vivre pour soi-même". As for the repetitive failures of health policies implemented in some African countries, the author proposes an analysis based on the "biopouvoir", explaining these failures by a deficiency, an absence, a bursting of it
NJANPOP, LAFOURCADE BERTHE-MARIE. "Contribution a l'etude epidemiologique descriptive de la tuberculose bovine et de son agent, mycobacterium bovis, dans le nord-cameroun". Paris 12, 1999. http://www.theses.fr/1999PA120060.
Mbwe, Mpoh Maurice. "Sécurité des antituberculeux utilisés dans la prise en charge de la tuberculose multirésistante". Electronic Thesis or Diss., Bordeaux, 2023. http://www.theses.fr/2023BORD0468.
Tuberculosis (TB) is a disease caused by Koch’s bacillus. It is the ninth leading cause of death worldwide, and the most common infectious cause of death, surpassing HIV/AIDS. The development of resistances due to misuse of anti-tuberculosis drugs has resulted in new forms of TB, including multidrug-resistant tuberculosis (MDR-TB). MDR-TB is a particularly dangerous form of tuberculosis, characterized by its resistance to both isoniazid and rifampicin, the two main and most effective anti-tuberculosis drugs. Developing countries, including Cameroon, are heavily affected. Effectively treating MDR-TB requires the combination of several drugs over several months. Indeed, from 2016 to 2020 the World Health Organization recommended the use of shorter treatment regimen for MDR-TB patients. This lasts for 9–11 months and is divided into two phases: An intensive phase, and a continuous ambulatory phase. The intensive phase involved 4–6 months of daily treatment with 6 antibiotics (moxifloxacin, protionamide, isoniazid high-dose, clofazimine, ethambutol, and pyrazinamide) associated with kanamycin or amikacin. The continuous ambulatory phase had a fixed treatment duration of 5 months with 4 antibiotics: Moxifloxacin, clofazimine, ethambutol, and pyrazinamide. The aim of this thesis was to assess the safety of anti-tuberculosis drugs used in the management of MDR-TB in Cameroon. Initially, we conducted a study to assess the safety profile of treatments used for MDR-TB in the main TB treatment center or hospital in Cameroon. This study identified aminoglycoside-related deafness as the main cause of treatment change or discontinuation. Secondly, we assessed compliance with WHO recommendations on MDR-TB treatment, as well as patient persistence with the program and the treatment. This study revealed very strong compliance with the WHO recommendations, although a progressive decline in persistence was recorded notably during the continuation phase. Finally, in view of the fact that during the course of our thesis, aminoglycosides were replaced by bedaquiline in the WHO-standardized MDR-TB treatment regimen, due to ototoxicity and other problems, we carried out a preliminary study on the safety and persistence of the new MDR-TB regimen. This work showed that ototoxicity problems disappeared, and that treatment persistence improved, while highlighting the risks of joint pain and cardiac problems associated with the new regimen. These results demonstrate that MDR-TB treatment regimens in Cameroon are consistently associated with adverse drug reactions despite changes in the medicines used. Thus, there is a need to implement a strong drug safety monitoring system which will allow health care providers and policy makers to continuously evaluate the safety profile of drugs in use and improve clinical outcomes. As the current treatment regimen is now bedaquiline-based, the strict monitoring of cardiovascular events is vital since other drugs like clofazimine, and moxifloxacin can also prolong the QT interval
Sousa, Erivelton de Oliveira. "Caracterização dos perfis genéticos e de resistência a fármacos de isolados de Mycobacterium tuberculosis associados com casos de tuberculose multirresistente na Bahia, Brasil". Centro de Pesquisas Gonçalo Moniz, 2012. https://www.arca.fiocruz.br/handle/icict/7159.
Made available in DSpace on 2013-10-15T19:41:49Z (GMT). No. of bitstreams: 1 Erivelton 1 Oliveira Souza Caracterizaçao dos perfis...2012.pdf: 2501634 bytes, checksum: c5ec35828b8fce881d7f6a1ae0ff2b45 (MD5) Previous issue date: 2012
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
A resistência aos fármacos utilizados no tratamento da tuberculose (TB) é um importante desafio no combate à doença. A rifampicina e a isoniazida são dois fármacos de primeira linha essenciais para a cura da doença, a qual tem como agente o M. tuberculosis. Pacientes com TB cujos isolados de M. tuberculosis apresentem resistência in vitro simultânea a estes dois fármacos desenvolvem a TB multirresistente (TBMR). A resistência do M. tuberculosis está relacionada com mutações em genes importantes para a sobrevivência do bacilo. O tratamento da TBMR é mais longo e utiliza fármacos anti-TB de segunda linha, os quais são de maior toxicidade, predispondo os pacientes à não adesão aos esquemas de tratamento. O paciente com TBMR, quando não devidamente tratado, pode selecionar cepas resistentes aos fármacos anti-TB de segunda linha, proporcionando o surgimento da TB extensivamente resistente (TBXDR). Por sua vez, estas cepas podem ser transmitidas em comunidades, constituindo um grave problema de saúde pública. Segundo a Organização Mundial de Saúde, a TBXDR tem sido documentada em alguns países, mas no Brasil estes dados são escassos. A caracterização genética de cepas de M. tuberculosis envolvidas com os casos TBMR/TBXDR pode facilitar a identificação de vias de transmissão. OBJETIVO: Pesquisar casos de TBXDR na Bahia e caracterizar perfis genéticos de isolados de M. tuberculosis de pacientes com TB multirresistente, associando o perfil genético encontrado com as características sócio-demográficas e clínicas dos pacientes envolvidos. MATERIAIS E MÉTODOS: Isolados de M. tuberculosis obtidos de pacientes com diagnóstico de TBMR entre 2008-2011 residentes no Estado da Bahia (Brasil) foram submetidos ao teste de sensibilidade utilizando fármacos anti-TB de primeira e segunda linha e genotipados pela técnica do Número Variável de Repetições em Tandem de Unidades Repetitivas Inter-espaçadas Micobacterianas (MIRU-VNTR) para obtenção de perfis genéticos que foram associados com perfis da base de dados internacional MIRU-VNTRplus. Isolados com perfis genéticos não associáveis a linhagens com o uso desta técnica foram adicionalmente genotipados por Spoligotyping e ambas as informações foram consideradas para assimilação de linhagens utilizando esta mesma base de dados. Informações clínico-epidemiológicas foram obtidas do banco de dados “Sistema TBMR” do Ministério da Saúde. RESULTADOS: Foram analisados 392 isolados. Destes, 35% foram excluídos por ausência de crescimento ou contaminação e 12% constituíam amostras em duplicata, resultando em 206 pacientes com TBMR no estudo. Comprovou-se a ocorrência da TBXDR em 7% (14/206) dos pacientes; destes, dois não possuíam registro anterior para qualquer tratamento anti-TB. Os pacientes estudados foram provenientes de 45 municípios do Estado. A capital, Salvador, concentrou 71% dos casos TBMR e 76% dos TBXDR. Dos casos TBXDR, 36% (5/14) apresentaram isolados resistentes a todos os fármacos testados. Observou-se associação de resistência combinada entre estreptomicina e etambutol (8/14, 57%) e o perfil TBXDR (RP 4,0; IC95% 1,2-13,8; P=0,01). Dos casos TBXDR, 71% (10/14) desenvolveram uma ou mais comorbidades (P=0,04), sendo o transtorno mental uma comorbidade significativa neste grupo (21%; 3/14; P=0,04). Encontrou-se 56 perfis genéticos, 38 únicos e 18 agrupados em clusters (contendo de 2 a 11 isolados). Quase a totalidade (92%) dos casos TBXDR esteve agrupada em clusters, diferindo dos casos não-TBXDR (P=0,049). Os perfis genéticos estiveram principalmente associados a seis famílias: LAM (70%), Cameroon (16%), Haarlem (10%) e as famílias X, S, Uganda I, que combinadas perfizeram 4%. Os casos TBXDR foram representados pelas famílias LAM (45%, ST’s 376, ST42, ST20), Cameroon (36%, ST61 único) e Haarlem (18%, ST50). CONCLUSÕES: A Bahia apresentou casos de TBXDR e as famílias de M.tuberculosis envolvidas com estes casos foram LAM, Cameroon e Haarlem. A genotipagem auxiliou na descoberta de casos epidemiologicamente relacionados.
Resistance to drugs used in tuberculosis (TB) chemotherapy is a major challenge to fighting this disease caused by M. tuberculosis. Rifampin and isoniazid are two main first-line drugs to achieve TB cure. TB patients whose M. tuberculosis isolates exhibit resistance simultaneously to these two drugs develop multidrug-resistant TB (MDR-TB). M. tuberculosis resistance is related to mutations in genes important for bacillus survival. MDR-TB treatment is longer and uses more toxic second-line anti-TB drugs, predisposing patients to non-adherence to treatment regimens. Patients with MDR-TB, when not properly treated, can select strains resistant to second-line anti-TB drugs leading to the emergence of extensively drug-resistant TB (XDR-TB). These strains can be transmitted in communities, constituting a serious public health problem. According to the World Health Organization, XDR-TB has been documented in some countries, but in Brazil these data are scarce. The genetic characterization of M. tuberculosis strains involved in MDR/XDR-TB cases could facilitate the identification of transmission chains. AIMS: To investigate cases of XDR-TB in Bahia and to characterize the genetic profiles of the isolates of M. tuberculosis from patients with multidrug-resistant TB, associating the genetic profiles observed with the socio-demographic and clinical characteristics of patients involved. MATERIALS AND METHODS: M. tuberculosis isolates obtained from patients diagnosed with MDR-TB between 2008-2011 resident in the State of Bahia (Brazil) were tested for sensitivity against first and second-line anti-TB drugs and genotyped by the Variable Number of Tandem Repeats in Repetitive Unit Inter- Mycobacterial spaced (MIRU-VNTR) technique to obtain the genetic profiles that were associated with profiles in the international database MIRU-VNTRplus. Isolates whose genetic profiles have not matched any lineage with the use of this technique were further genotyped by Spoligotyping and information from both methods were considered to test for the possible matching with lineages from the same database. Clinical and epidemiological data were obtained from the database "Sistema TBMR" of the Ministry Health. RESULTS: We analyzed 392 isolates. Of these, 35% were excluded due to absence of growth or contamination and 12% corresponded to duplicate samples, resulting in 206 patients with MDR-TB in the study. XDR-TB was found in 7% (14/206) of the patients, two of which had no previous record of any anti-TB treatment. The patients studied were from 45 cities of the State. The capital, Salvador, concentrated 71% of all MDR-TB and 76% of the XDR-TB cases. Among XDR-TB cases, 36% (5/14) had isolates resistant to all drugs tested here. Combined resistance to streptomycin and ethambutol (8/14, 57%) was associated with the XDR-TB profile (OR 4.0, 95% CI 1.2 to 13.8, P = 0.01). 71 %(10/14) of XDR-TB cases developed one or more comorbidities (P= 0.04), mental disorder being a significant comorbidity in this group (21%, 3/14, P=0.04). Genotyping yielded 56 profiles, 38 unique and 18 in clusters (containing 2 to 11 isolates). Almost all (92%) XDR-TB cases were clustered, differing from non-XDR-TB cases (P=0.049). The genetic profiles were mainly associated with six families: LAM (70%), Cameroon (16%), Haarlem (10%), and the families X, S, Uganda I, which altogether amounted to 4%. The XDR-TB cases were represented by LAM (45% ST's 376, ST42, ST20), Cameroon (36%, single ST61) and Haarlem (18% ST50). CONCLUSIONS AND STUDY CONTRIBUTIONS: Bahia presented cases of XDR-TB and the families involved with these cases were LAM, Haarlem and Cameroon. Genotyping helped in epidemiologically linked case finding.
Moualeu-Ngangue, Dany Pascal [Verfasser]. "A Mathematical Tuberculosis Model in Cameroon / Dany Pascal Moualeu-Ngangue". Berlin : Freie Universität Berlin, 2013. http://d-nb.info/1043198164/34.
Awah, Ndukum Julius. "Epidemiology and public health significance of bovine tuberculosis in cattle in the highlands of Cameroon". Thesis, University of Plymouth, 2012. http://hdl.handle.net/10026.1/913.
Kelly, Robert Francis. "Epidemiology of bovine tuberculosis and influence of liver fluke co-infection in Cameroon, Central Africa". Thesis, University of Edinburgh, 2017. http://hdl.handle.net/1842/29560.
Njozing, Barnabas N. "Bridging the Gap : implementing tuberculosis and HIV/AIDS collaborative activities in the Northwest Region of Cameroon". Doctoral thesis, Umeå universitet, Institutionen för folkhälsa och klinisk medicin, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-43847.
Introduction L’épidémie du virus de l’immunodéficience humaine (VIH) a conduit à une augmentation globale de la tuberculose(TB), particulièrement dans les régions à forte prévalence du VIH. Il y’avait par le passé un manque de coordination tant sur le plan mondial que national, des programmes de lutte contre la TB et le VIH pour freiner les effets dévastateurs liés à la co-infection des deux pathogènes. Cependant, l’initiative pilote “ProTEST” conduite en 1997 en Afrique sub-saharienne a démontré que les programmes de lutte contre le VIH et la TB pouvaient collaborer avec succès en combinant leurs services. Cette étude pilote a inévitablement incité a un changement de politique du bureau intérimaire a l’Organisation Mondiale de la Santé (OMS), de lutte contre le VIH/TB à mettre sur pieds en 2004 des objectifs pour la réduction de l’impact du VIH/TB parmi les populations atteintes des deux infections. Cette thèse explore comment la collaboration entre les activités des programmes de lutte VIH/TB a été établie au Cameroun, et comment son application se fait dans la région du nord ouest. Il est également mis en exergue et les réalisations les difficultés que rencontrent les services combinés lors de la dispensation des soins aux malades de TB avec une coïnfection au VIH. Méthodes L’étude a été faite dans la région du nord ouest, une des 10 régions du Cameroun, avec le taux de prévalence au VIH le plus élevé. L’étude utilise le système de recherche en santé combinant des méthodes qualitatives et quantitatives pour explorer les objectifs de la recherche. Les méthodes qualitatives ont été utilisées pour enregistrer les données suivantes: i) centre offrant les services combinés; les personnes en charge au niveau central, régional, et des districts, qui sont responsables de l’intégration au processus et qui d’autre part veillent a ce que les malades de TB bénéficient des services du VIH ; et ii) les malades de TB qui considèrent le dépistage du VIH comme porte d’entrée dans les services VIH. Des méthodes quantitatives ont été utilisées pour confirmer l’accès des malades de TB aux soins de services VIH offerts par la collaboration. Résultats L’étude a démontré que bien qu’il y ait plusieurs niveaux de collaborations entre les programmes de VIH et TB depuis le sommet jusqu’ à la base du système de santé, la provision de services combinés est faisable. Malgré les difficultés rencontrées par les malades de TB pour avoir accès au dépistage du VIH, l’application en somme de la collaboration des activités entre les programmes de VIH et de TB a augmenté l’acceptation et l’accessibilité des malades de TB aux services de VIH. Ceci fut facilité par l’amélioration de la coopération au niveau des opérations des deux programmes permettant ainsi la facilitation de l’établissement d’une alliance entre le personnel de soin et le patient, alliance qui fut primordiale dans l’élaboration du rapport de confiance que le malade doit avoir à l’endroit du system de santé. La collaboration a également conduit à un travail d’équipe et une formation croisée entre les équipes des deux programmes, il a été également établi une amélioration du réseau d’échange entre les personnels de soins et toutes personnes actives dans le secteur du VIH et TB. Néanmoins, il a été relevé des défis dans le système de santé telle une insuffisance dans le leadership et la gestion de fréquente interruption dans la chaine de distribution des médicaments essentiels et du matériel de laboratoire. Conclusion La collaboration des activités des programmes VIH/TB a amélioré la qualité des soins et services avec pour résultante une meilleure accessibilité des malades de TB aux services de VIH. Néanmoins, une conduite appropriée qui garantie une planification mixte, une évaluation et un suivi des activités essentielles, ainsi qu’une gestion fiable a tous les niveaux du système de santé est indispensable. Outre, les difficultés liées au système de santé identifiées par cette étude et qui méritent une évaluation, du fait qu’elles pourraient affecter négativement l’application effective du but recherché et la collaboration durable entre les deux services.
Libri sul tema "Tuberculose – Cameroun":
Vidal, Laurent. Sida et tuberculose: la double peine?: Institutions, professionnels et sociétés face à la coinfection au Cameroun et au Sénégal. Louvain-la-Neuve: Academia Bruylant, 2011.
Tantchou, Josiane. Epidémie et politique en Afrique: Maladie du sommeil et turberculose au Cameroun. Paris: Harmattan, 2007.
Capitoli di libri sul tema "Tuberculose – Cameroun":
Awah-Ndukum, Julius, Nkongho Franklyn Egbe e Victor Ngu-Ngwa. "The Status of Bovine Tuberculosis in Cameroon". In Tuberculosis in Animals: An African Perspective, 283–303. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-18690-6_12.
S. Avumegah, Michael. "Mycobacterium ulcerans Disease and Host Immune Responses". In New Advances in Neglected Tropical Diseases [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.103843.
Ibeneme, Sunny, Nkiruka Ukor, Joseph Okeibunor e Felicitas Zawaira. "Geospatial Clustering of Mobile Phone Use and Tuberculosis Health Outcomes among African Health Systems". In Healthcare Access [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.98528.
Atti di convegni sul tema "Tuberculose – Cameroun":
MOUALEU, D. P., S. BOWONG e J. KURTHS. "PARAMETER ESTIMATION OF A TUBERCULOSIS MODEL IN A PATCHY ENVIRONMENT: CASE OF CAMEROON". In International Symposium on Mathematical and Computational Biology. WORLD SCIENTIFIC, 2014. http://dx.doi.org/10.1142/9789814602228_0021.
Mbatchou Ngahane, B. H., S. Gaping Simen, M. P. Halle, C. Okalla e I. A. Goupeyou Wandji. "Prevalence of Tuberculosis and Its Factors Among Patients on Maintenance Dialysis in Douala, Cameroon". In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5146.
Andoseh, Genevieve, Lionel Ulrich Tiani, Axel Cyriaque Ambassa, Jean Paul Assam Assam, Fossi Cedric Tchinda, Nkah Leonard Numfor, Joseph Kamgno, Francine Ntoumi e Véronique Beng Penlap. "PA-562 Epidemiology of HIV and Helminth co-infection among pulmonary tuberculosis patients at Jamot hospital in Yaoundé, Cameroon". In Abstracts of The Eleventh EDCTP Forum, 7–10 November 2023. BMJ Publishing Group Ltd, 2023. http://dx.doi.org/10.1136/bmjgh-2023-edc.235.